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Abstract 
In recent years there has been increased interest in the problem of 
reducing cardiovascular risk in patients with rheumatoid arthritis (RA). To 
this end it is proposed to use statins, the effects of which are now being 
actively studied. The purpose of this work is to determine the possibility of 
use of atorvastatin in patients with RA and hypercholesterolemia. The study 
included 42 patients with RA and moderate hypercholesterolemia and 26 
practically healthy women (control). We studied lipid spectrum, DAS28, 
levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), 
tumor necrosis factor-alpha (TNF-alpha), interleukin 1β, 10 (IL-1β, IL-10), 
matrix metalloproteinase-9 (MMP-9) and its complex with tissue inhibitor-2 
(MMP-9/TIMP-2). Patients with RA and moderate hypercholesterolemia in 
the complex therapy atorvastatin were administered at a dose of 20mg per 
day. We analyzed the stated figures in these patients before and after 6 weeks 
of treatment. In all patients with RA and moderate hypercholesterolemia on 
therapy with atorvastatin decreased total cholesterol (TC), low-density 
lipoprotein (LDL) and triglycerides (TG), indicators DAS28, ESR, CRP, 
concentrations of TNF-alpha, IL-1β, IL-10, MMP-9, MMP-9/TIMP-2. These 
data prove lipid-reducing and anti-inflammatory effects of atorvastatin, that 
allows to consider the application of this drug in patients with RA 
hypercholesterolemia in the complex therapy to reduce cardiovascular risk. 
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Introduction 
Cardiovascular pathology acts as the most common comorbid 
conditions in patients with RA and occurs in approximately one third of 
people suffering from this disease (C. Meune, E. Touzé, L. Trinquart, Y. 
Allanore, 2009; M.J. Peters, D.P. Symmons, D.W. McCarey et al., 2010). In 
numerous studies have shown that the RA development of atherosclerosis 
and related cardiovascular complications due not only to the traditional risk 
factors (NCEP) (M.J. Peters, D.P. Symmons, D.W. McCarey et al., 2010; 
T.V. Popkova, D.S. Novikova, E.L. Nasonov, 2012), and inflammatory 
mechanisms underlying pathogenesis of these diseases (P.Libby, 2008; F. 
Montecucco, F. Mach, 2009).  
Deficiencies in the system of transport of TC play an important role 
in the development of atherosclerosis and RA. As is known, high levels of 
LDL, the prevalence in the spectrum of small, dense LDL particles and low 
value high density lipoprotein (HDL), hypertriglyceridemia are the principal 
determinants of high risk of development of atherosclerosis (M.J. Peters, 
D.P. Symmons, D.W. McCarey et al., 2010; T.V. Popkova, D.S. Novikova, 
E.L. Nasonov, 2012). 
An important role in the development of cardiovascular 
complications in RA plays the severity of the disease, characterized by high 
joint account, the presence of extra-articular manifestations, expressed 
functional failure of joints, positivity in respect of rheumatoid factor and 
antibodies to cyclic caroliniana peptide and high levels of markers of 
inflammation (ESR, CRP, IL-1, TNF-alpha, etc.) (F. Montecucco, F. Mach, 
2009; T.V. Popkova, D.S. Novikova, E.L. Nasonov, 2012). 
The cause of chronic inflammation in RA is the imbalance between 
the production of proinflammatory (TNF-alpha, IL-1, -6, -8, -12, -15 and 
others) and anti-inflammatory (IL-4, -10, receptor antagonist of IL-1 and 
others) cytokines with a predominance of products over the first synthesis of 
the second (I.B. McInnes, G. Schett, 2007; A.A. Novikov, E.N. 
Aleksandrova, M.A. Diatroptova, E.L. Nasonov, 2010; V.S. Sviridova, E.N. 
Kologrivova, N.A. Pronina et al., 2011).  
Recently, great attention of the authors aimed to investigate the role 
of matrix metalloproteinases (MMP) and tissue inhibitors (TIMP) in the 
pathogenesis of atherosclerosis and coronary heart disease, including patients 
with RA (N.P. Mitkovskaya, T.A. Kurak, L.L.  Avdej  et al., 2011; A.A. 
Turna, R.T. Toguzov, 2009). Works related to the definition of activity of 
MMP in clinical practice, a little bit, and mostly they are presented 
experimental research. 
Systemic inflammation in patients with RA promotes greater severity 
of processes and endothelial metalloproteinases activation with increased 
content in the blood MMP-9 (N.P. Mitkovskaya, T.A. Kurak, L.L.  Avdej  et 
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al., 2011). High serum activity of MMP-9 is an indicator of unstable 
atherosclerotic plaques in acute coronary syndrome and help to identify 
patients with an increased risk of adverse cardiovascular events (N.M. 
Lupach, E.A. Khludeeva, V.N. Potapov, P.A. Lukyanov, 2010].  
TIMPs play an important role in keeping MMPs in latent form and 
preventing their excessive activation. Among them TIMP-1, TIMP-2 
regulate the enzymatic activity of MMP in vivo. For normal processes of 
reorganization of the extracellular matrix is a need to balance the activity of 
MMP and their inhibitors (A.A. Turna, R.T. Toguzov, 2009). 
Now to slow the progression of atherosclerotic vascular lesions and 
reduce the risk of cardiovascular accidents in RA was suggested to use 
statins (A.A. Novikov, E.N. Aleksandrova, M.A. Diatroptova, E.L. Nasonov, 
2010; D.S. Novikova, T.V. Popkova, E.L. Nasonov, 2010; V.S. Tutunov, 
M.Y. Zubareva, P.P. Malyshev,  V.V. Kukharchuk, 2011). In addition to 
improving lipid metabolism, are studied pleiotropic, namely anti-
inflammatory effects of statins, which allows to discuss the prospects of their 
application in the treatment of RA (S. Van Doornum, G. McColl, I.P. Wicks, 
2004; A.A. Novikov, E.N. Aleksandrova, M.A. Diatroptova, E.L. Nasonov, 
2010; V.V. Yarosh, O.V. Radchenko, 2010). 
There are few studies on the use of statins in RA. Mainly work in this 
area is devoted to the study of the effect of simvastatin and atorvastatin, and 
today the main focus of attention is paid to the application of the drug in 
patients with RA (classic study TARA (Trial of Atorvastatin in Rheumatoid 
Arthritis), completed in 2004 (D.W. McCarey, I.B. McInnes, R. Madhok et 
al., 2004), from 2011 launched 5-year-old largest clinical study TRACE RA 
(TRial of Atorvastatin for the Primary Prevention of Cardiovascular Events 
in Rheumatoid Arthritis) (V.S. Tutunov, M.Y. Zubareva, P.P. Malyshev,  
V.V. Kukharchuk, 2011). 
Thus, the study of the application of atorvastatin in patients with RA 
and hypercholesterolemia is important for timely correction of 
cardiovascular risk, which in the future could reduce mortality from 
cardiovascular complications of RA. 
The aim of the present work is to study of the dynamics of lipid 
spectrum, of activity indicators of RA (ESR, DAS 28), cytokine profile 
(TNF-alpha, IL-1-beta, IL-10), concentrations of MMP-9 and complex 
MMP-9/TIMP-2 in using of atorvastatin in patients with RA and 
hypercholesterolemia. 
 
Material and methods 
He studied the possibility of application of atorvastatin in 42 women 
aged 38 to 59 years with reliable diagnosis seropositive RA and moderate 
hypercholesterolemia IIA and IIb types on Fredriksen without clinical 
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manifestations of cardiovascular disease. Control was 26 practically healthy 
women at the age from 33 to 59 years, not having hypercholesterolemia and 
diseases of musculoskeletal apparatus. The research was carried out on the 
basis of Primorsky rheumatology center of Primorsky regional clinical 
hospital №1 (Vladivostok, Russian Federation). 
The diagnosis of RA verified on the basis of the criteria proposed by 
American College of Rheumatology (ACR, 1987) and revised by American 
College of Rheumatology and European League Against Rheumatism 
(EULAR, 2010) (D. Aletaha, T. Neogi, A.J. Silman et al., 2010). Duration of 
RA in the monitoring group ranged from 4 months to 18 years of age. 
Prevailed patients with moderate disease activity (average index DAS28 
4,84±0,12). As a basic treatment of the patient was receiving a stable dose of 
methotrexate 10-20 mg per week in combination with folic acid, and also as 
a pathogenetic and symptomatic therapy, nonsteroidal anti-inflammatory 
drugs, the majority of patients took prednisone in the dose of 10-15 mg per 
day. Patients in the study group atorvastatin was administered at a dose of 20 
mg per day for 6 weeks.  
Exclusion criteria patients were: cardiovascular disease, including 
detection during instrumental examination (X-ray of the chest, according to 
electrocardiogram, ultrasound of the heart) subclinical lesions of the 
cardiovascular system; liver disease; diabetes mellitus, renal insufficiency, 
contraindications for purpose of basic and lipid-lowering therapy; in history 
for the last 5 years any malignant tumors; alcohol and drug dependence; 
pregnancy and lactation.  
The thorough clinical examination was conducted all patients. TC, 
TG, HDL was determined in blood serum enzymatic method. Level of LDL 
was calculated by the formula W.T. Friedewald: 
LDL = TC - HDL - TG/2,2,  
where LDL - cholesterol of low density lipoprotein, TC - total 
cholesterol, HDL - lipoproteins of high density, TG – triglycerides.  
The activity of rheumatoid arthritis was assessed by indicators 
DAS28, levels ESR, CRP. Concentrations of TNF-alpha and IL-1β, IL-10, 
MMP-9 and complex MMP-9/TIMP-2 in the blood serum of the examined 
patients was determined highly sensitive immunoassay methods with the 
help of test-systems of the company "R&D Systems" (USA). 
After 6 weeks was re-assessed the above clinical and laboratory 
parameters. 
Statistical processing of the material was carried out by methods of 
parametric statistics using the built package of the statistical analysis with 
Microsoft Excel and Statuistica 6.0. Data are presented as the arithmetic 
mean (M) and its error (m). The statistical significance of differences was 
estimated by t-student test. Differences between groups were considered 
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statistically significant when p<0,05 (the probability of erroneous judgments 
less than 5%). 
 
Results  
The study involved RA patients with moderate hypercholesterolemia. 
The initial concentration of TC, LDL, TG in these patients was higher in 
comparison with the control group - TC 7,21±0.08 and 4,53±0.11 mmol/l, 
LDL 3,91±0.12 and 2,17±of 0.07 mmol/l, TG 1,47±0.03 and 0,91±0.03 
mmol/l, respectively (p<0.001). HDL in patients in both groups the original 
had no significant differences (p>0.05).  
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Figure 1. Dynamics of average lipid spectrum in patients with RA moderate hypercholesterolemia 
before and after treatment with atorvastatin, M±m (mmol/l). 
 
After 6 weeks of starting treatment with atorvastatin was showed a 
significant decrease of the levels of TC by 29%, LDL by 31%, TG - 19% 
(p>0.05). The concentration of HDL in patients with RA and moderate 
hypercholesterolemia before and after 6-week lipid-lowering therapy has not 
changed. According to the data presented in figure 1, levels of TC and its 
fractions almost began to correspond to the norm.  
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Table 1. Dynamics of immune markers of inflammation and cytokines in patients with RA 
and moderate hypercholesterolemia before and after treatment with atorvastatin, M±m 
Parameter Control 
n=26 
Before treatment 
n=42 
After treatment 
n=42 
ESR, mm/h 6,18±0,57 28,46±4,11 20,12±3,34 
CRP, mkmol/ml 4,12±0,18 42,96±6,68 12,41±2,26 
DAS28 - 4,84±0,27 2,88±0,11 
IL-1β, pkg/ml 0,39±0,08 4,02±0,29 2,43±0,19 
TNF-α, pkg/ml 2,49±0,31 13,89±1,55 8,37±1,02 
IL-10, pkg/ml 2,41±0,52 11,42±1,61 7,81±0,92 
The difference with the control and group "Before treatment" statistically significant. 
 
After 6 weeks of starting treatment with atorvastatin is decreased 
activity of the RA to the minimum extent (table 1). In the dynamics of 
indicators ESR and CRP decreased almost to normal, but did not reach the 
levels in the control group. The analysis of changes from the side markers of 
immune inflammation in RA patients with moderate hypercholesterolemia 
was found to increase in all indicators - ESR, CRP, IL-1β, TNF-alpha, IL-10 
in comparison with the control group (p<0.001). The source patients were 
registered moderate level of activity of the RA. The highest level of increase 
among all the studied cytokines in comparison with indexes in the control 
group reached IL-1β. The concentrations of all cytokines were decreased in 
1,5-2 times on a background of treatment with atorvastatin, but remained 
higher than in the control group. 
Table 2. Indicators of changes in MMP-9 and complex MMP-9/TIMP-2 in patients with RA 
and moderate hypercholesterolemia before and after treatment with atorvastatin, M±m 
Parameter Control 
n=26 
Before treatment 
n=42 
After treatment 
n=42 
MMP-9, ng/ml 234,83 ± 11,38 337,14 ± 14,68 268,21 ± 13,24 
MMP-9/TIMP-2, ng/ml 7,83 ± 1,69 19,96 ± 2,04 12,42 ± 1,87 
The difference with the control and group "Before the treatment" statistically significant. 
 
The original levels of MMP-9 and complex MMP-9/TIMP-2 in the 
blood serum of patients with RA and moderate hypercholesterolemia were 
higher than in the control group (p<0.001) - 1.5 and 2.5 times respectively 
(table 2). In the dynamics of the treatment is marked decline in these indices. 
However, the content of MMP-9 and complex MMP-9/TIMP-2 in patients 
with RA and moderate hypercholesterolemia after treatment with atorvastatin 
do not reach those in the control group. 
 
Discussion 
The original everyone who participated in the study RA patients with 
moderate hypercholesterolemia was identified atherogenic lipids spectrum - 
elevated levels of LDL cholesterol, triglycerides, combined with the normal 
concentration of HDL cholesterol. As a result of atorvastatin after 6 weeks 
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showed a significant decrease in total cholesterol and atherogenic fractions 
(LDL, TG) on 19-31% from baseline almost to normal values. The 
concentration of HDL for the whole period of the study was not significantly 
changed and varied within limits. 
The original everyone who participated in the study RA patients with 
moderate hypercholesterolemia noted moderate inflammatory activity. For 
the period of treatment with atorvastatin dose of 20 mg per day on obligatory 
condition of reception of the basic anti-inflammatory drugs all indicators of 
systemic inflammation were decreased and became characteristic of the 
minimal activity of the RA. 
The data we obtained coincides with literature data of ukrainian 
authors (V.V. Yarosh, O.V. Radchenko, 2011), russian reseachers (N.M. 
Nikitina, A.P. Rebrov, 2010). In these studies, in appointing patients RA 
without cardiovascular disease, but with the presence of dyslipidemia 
atorvastatin in dose 10 and 20 mg/day is also marked by a significant 
reduction of the levels of total cholesterol, LDL cholesterol, triglycerides and 
activity of the RA. 
Our results partially correlates with the data of Van Doornum S. et al. 
(2004), in which atorvastatin dose of 20 mg was significantly reduced total 
cholesterol, LDL cholesterol, especially in patients with high activity, 
however, the levels of CRP, ESR not changed. 
Patients included in our study noted the good tolerability of all drugs. 
Side effects during the observation period were not registered. 
 
Conclusion 
Thus, when using atorvastatin in combination therapy RA are 
achieved lipid-reducing and anti-inflammatory effects. The use of 
atorvastatin in patients with RA and hypercholesterolemia is expedient to 
reduce the risk of cardiovascular complications and augmentation of anti-
inflammatory action the basic drugs. 
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